DataHodgkin lymphoma

Direct links plus the targets, companies, and technologies of this cancer's products.

• Living with and after Hodgkin lymphoma, the decisions and the people who make them: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026.
• On the forty-year figures. The second-cancer and cardiovascular cumulative incidences quoted on this page come from two Dutch cohorts treated between 1965 and 2000 with the radiotherapy fields and doses of that era, which are far larger than anything given now. They describe what happened to those cohorts. What modern fields and PET-guided de-escalation are worth over forty years is not yet known, because the cohort that would measure it has not been followed for forty years. The reason to carry the figures anyway is that the screening programmes attached to them are the thing a survivor can act on, and the commonest failure is not being enrolled in one.
• Taxonomy. The two classifications of 2022 disagree about the name of the non-classical form. The International Consensus Classification renamed nodular lymphocyte predominant Hodgkin lymphoma to nodular lymphocyte predominant B-cell lymphoma by consensus, because it differs biologically and clinically from classic Hodgkin lymphoma and is closely related to T-cell/histiocyte-rich large B-cell lymphoma. WHO-HAEM5 kept the old name so as not to interfere with trials in progress, while stating that the new name is acceptable in preparation for adopting it. The corpus keeps the record under the WHO-HAEM5 name and carries the other as an alias. Both books leave the four subtypes of classic Hodgkin lymphoma unchanged and both note that with modern treatment those subtypes have lost most of their prognostic meaning.

The same record for scripts and assistants; checked 2026-09-07. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.